From: Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma
Integrin Inhibitor | Targeted integrin | Effect on metastatic melanoma | Clinical trial | Phase of the clinical trial |
---|---|---|---|---|
MK-0429 | αvβ3 | Reduce lung metastasis of melanoma in mouse models [76] | – | – |
Intetumumab (CNTO 95) | αv | Inhibits melanoma cell adhesion, migration and invasion in vitro. Inhibit tumor growth in mouse xenografts of melanoma. | NCT00246012 | Phase I/II [116] |
Abergrin (eteracizumab, MEDI-522) | αvβ3 | Patients treated with Abergrin + decarbacine did not show survival benefit compared to decarbacine alone. | NCT00111696 NCT00066196 | |
Cilengitide (EMD 121974) | αvβ3 and αvβ5 | It was well tolerated but achieved minimal efficacy when used as a single-agent treatment. | NCT00082875 | Phase II [120] |
Volociximab (M200) | α5β1 | It was well tolerated at 10 mg/kg Q2W, and achieved preliminary clinical effect: SD was observed in 32/37 (87%) of patients. | NCT00099970 | Phase II [130] |